Targeted therapies in control of EMT in carcinoma and fibrosis
Authors:
- Kian-Ngiap ChuaKCKian-Ngiap Chua
- Jing MaJMJing Ma
- Jean-Paul ThieryJTJean-Paul Thiery
- 1 December 2007
- journal article
- review article
- Published by Elsevier in Drug Discovery Today: Disease Mechanisms
- Vol. 4 (4) , 261-267
Abstract
No abstract availableThis publication has 53 references indexed in Scilit:
- Signaling networks guiding epithelial–mesenchymal transitions during embryogenesis and cancer progressionCancer Science, 2007
- Next generation molecular targeted agents for breast cancer: focus on EGFR and VEGFR pathwaysBreast Cancer, 2007
- Complex networks orchestrate epithelial–mesenchymal transitionsNature Reviews Molecular Cell Biology, 2006
- Role of Tyrosine Kinase Inhibitors in Cancer TherapyThe Journal of Pharmacology and Experimental Therapeutics, 2005
- A Pooled Analysis of Bone Marrow Micrometastasis in Breast CancerNew England Journal of Medicine, 2005
- Clinical Significance of Immunocytochemical Detection of Tumor Cells Using Digital Microscopy in Peripheral Blood and Bone Marrow of Breast Cancer PatientsClinical Cancer Research, 2004
- Epithelial–mesenchymal transitions in development and pathologiesCurrent Opinion in Cell Biology, 2003
- Epithelial–mesenchymal transitions in tumour progressionNature Reviews Cancer, 2002
- Cell Signaling by Receptor Tyrosine KinasesCell, 2000
- Lack of Effect of Adjuvant Chemotherapy on the Elimination of Single Dormant Tumor Cells in Bone Marrow of High-Risk Breast Cancer PatientsJournal of Clinical Oncology, 2000